Gilead
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says
August 8, 2019Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma
Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …
Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes
July 23, 2019Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus
Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …
Gilead invests $5.1 billion into Galapagos NV
July 15, 2019Sales and Marketing Galapagos, Gilead, biotech, collaboration, deal, drug discovery, pharma
Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV. The collaboration will see Gilead invest $5.1 …
ViiV Healthcare’s two drug HIV therapy beats Gilead’s three drug treatment in Phase 3 trial
July 10, 2019Research and Development AIDS, Dovato, GSK, Gilead, HIV, ViiV, pharma
Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint …
US Government awarded new patent on preventative HIV drugs PrEP
July 3, 2019Research and Development, Sales and Marketing Gilead, HHS, government, pharma
The Department of Health and Human Services (HHS) has been awarded a new patent on drugs that prevent HIV. The …
Gilead signs deal with Nurix Therapeutics worth more than $2.3 billion
June 20, 2019Business Services, Research and Development Gilead, Nurix Therapeutics, pharma, protiens
Gilead has signed a deal with San Francisco biotech Nurix Therapeutics – a company focused on developing drugs that control …
Gilead inks deal with Canadian antibody discovery firm AbCellera
June 14, 2019Medical Communications AbCellera, Gilead, monoclonal antibodies, pharma
Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera. The two firms will take part in …
Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
May 30, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada
May 17, 2019Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma
On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …
Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says
May 15, 2019Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …
Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
May 10, 2019Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
